New hope for cervical cancer patients who Can't take chemo

NCT ID NCT07450963

Not yet recruiting Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests a drug called cadonilimab combined with radiation therapy for women with advanced cervical cancer who cannot receive standard chemotherapy due to age or health issues. The study will enroll 45 participants and measure how many have a complete response (no cancer detected) after treatment. The goal is to see if this combination can improve outcomes compared to radiation alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cadonilimab (a drug that helps the immune system fight cancer)
What this could lead to: If successful, this could offer a new treatment option for cervical cancer patients who cannot receive standard chemotherapy, potentially improving tumor shrinkage and long-term control.
What could go wrong: This is a small, early-phase trial (45 people) with no control group. The combination may not work better than radiotherapy alone, and side effects from the immune drug could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED CERVICAL CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.